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Dear Editor,
Recently, Schüpke and colleagues performed an
investigator-initiated head-to-head trial on prasugrel versus
ticagrelor in acute coronary syndrome [1]. We highly com-
mend the authors for performing such study. Certainly, given
the earlier trials comparing prasugrel and ticagrelor to
clopidogrel [2, 3], which influencedmany national guidelines,
these trials [2, 3] demonstrated absolute risk reductions of 2%
for both ticagrelor and prasugrel versus clopidogrel. It was
now shown that prasugrel led to lower primary endpoint
(i.e., 12- and 15-monthmortality) than ticagrelor. As a thought
experiment, we wondered whether the results of the three
trials could be reconciled to make a practice recommendation.
For this reason, in this letter, we present a reflection of our
journey in achieving this purpose.
Sample Size and Power Issue
As a start, we noted that the sample size calculation in
Schüpke et al. [1] may be biased and not based on
existing literature. The primary endpoint in the prasugrel
arm in Wiviott et al. [2] occurred less frequently (~ 9.3%)
than assumed by the authors in their power calculation
(12.9%), suggesting that the sample size may be too small
to effectively estimate a difference. Though, one could
have based this assumption on the previous trials, rather
than guessing 12.9%. Due to this reason, the study may
suffer from a power issue.
Pooling the Data
The power issue gave rise to our direction to attempt to rec-
oncile the three trials by pooling the data. In order to do so, we
requested the individual patient data for the respective corre-
sponding authors [2, 3], but unfortunately, this was unavail-
able for physicians. Therefore, we had to work with the pub-
lished data in the respective studies. Qualitative inspection of
the baseline tables showed that the samples were more or less
comparable (see Supplementary Material Table A). This
allowed us to pool the data and estimate the odds ratios
(OR) and 95% confidence intervals (95% CI). Taken together,
the fact that we did not have any information on censoring and
the power calculations were done based on chi-square test, we
opted for calculating ORs rather than summarizing the hazard
ratios.
Interestingly, the pooled estimate of the prevalence of
the primary endpoint was not significantly different for
prasugrel (9%) and ticagrelor groups (10%, OR = 1.05,
95% CI 0.95–1.16; Table 1), while we can conclude
that clopidogrel is inferior to both prasugrel and
ticagrelor (p < 0.05).
Of course, such pooling comes with limitations. The
primary endpoint differed slightly between the trials (1)
definitions of events (Schüpke et al. [1]: death from car-
diovascular cause, nonfatal myocardial infarction (MI), or
nonfatal stroke; Wiviott et al. [2]: death from cardiovas-
cular cause, MI, or stroke; Wallentin et al. [3]: death from
vascular cause, MI, or stroke) and (2) the follow-up dura-
tion (Wiviott et al. [2]: 15 months and reporting a slightly
lower event rate at 12 months; versus 12 months in the
other two trials). Though, one may expect with the con-
stant hazard ratio assumption that the proportions are sim-
ilar at the 1-year mortality cutoff. (3) A major difference
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between the three trials was the prevalence of STEMI,
which varied between 20 and 40%. This may have influ-
enced the results, but unfortunately, we were unable to
control for this factor.
To conclude, given the power issue in the Schüpke et al.
trial [1], it leads us to pool the primary outcomes for
clopidogrel, prasugrel, and ticagrelor. Based on these analy-
ses, we conclude that clopidogrel is inferior to prasugrel and
ticagrelor, but the latter two have similar outcomes. Future
research, e.g., by means of re-analyzing the existing data, is
needed to define sub-groups of acute coronary syndrome and
test whether prasugrel (a thienopyridine) or ticagrelor (a cy-
clo-pentyltriazolo-pyrimidine) is the best treatment option for
which of these groups.
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